What is it about?
Prostascint scan besides detecting lymph node metastases from prostate carcinoma can also show uptake in malignancies like renal cell carcinoma, which express prostate-specific membrane antigen (PMSA).
Featured Image
Why is it important?
Though ProstaScint uptake in renal cell carcinoma and in metastatic retroperitoneal lymph nodes from prostate cancer may be seen in clinical practice, this combination has not been reported previously. Therefore, the possibility of In‑111 ProstaScint® uptake in malignancy other than prostate cancer should be considered when abnormal findings on In‑111 ProstaScint® study are atypical for the distribution of prostate cancer, and correlation with anatomic imaging is warranted to clarify the nature and significance of the uptake.
Perspectives
One should keep one's eyes open for areas of uptake in the "corners" of the image where one might find unexpected uptake in studies like Prostascint scan while always keeping in mind that malignancies other than Prostate cancer can also show uptake on a Prostascint scan.
Dr Tanvir Rizvi
University of Virginia
Read the Original
This page is a summary of: Indium-111 Capromab Pendetide (ProstaScint ® ) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma , World Journal of Nuclear Medicine, January 2015, Medknow,
DOI: 10.4103/1450-1147.163259.
You can read the full text:
Contributors
The following have contributed to this page
